Galectin Therapeutics Inc. (GALT) Reveals an Earnings Mystery

Galectin Therapeutics Inc. (NASDAQ:GALT) went up by 32.36% from its latest closing price compared to the recent 1-year high of $4.50. The company’s stock price has collected 36.33% of gains in the last five trading sessions. Press Release reported on 09/22/20 that Galectin Therapeutics Announces Investor Conference Call and Webinar on September 29, 2020

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Is It Worth Investing in Galectin Therapeutics Inc. (NASDAQ :GALT) Right Now?

Plus, the 36-month beta value for GALT is at 2.27. Opinions of the stock are interesting as 2 analysts out of 2 who provided ratings for Galectin Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

The average price from analysts is $8.00. GALT currently public float of 41.17M and currently shorts hold a 12.39% ratio of that float. Today, the average trading volume of GALT was 172.82K shares.

GALT’s Market Performance

GALT stocks went up by 36.33% for the week, with a monthly jump of 31.41% and a quarterly performance of 19.74%, while its annual performance rate touched 0.28%. The volatility ratio for the week stands at 15.16% while the volatility levels for the past 30 days are set at 7.60% for Galectin Therapeutics Inc.. The simple moving average for the period of the last 20 days is 32.40% for GALT stocks with a simple moving average of 40.07% for the last 200 days.

Analysts’ Opinion of GALT

Many brokerage firms have already submitted their reports for GALT stocks, with H.C. Wainwright repeating the rating for GALT by listing it as a “Buy.” The predicted price for GALT in the upcoming period, according to H.C. Wainwright is $12 based on the research report published on August 13th of the current year 2020.

B. Riley FBR, on the other hand, stated in their research note that they expect to see GALT reach a price target of $11. The rating they have provided for GALT stocks is “Buy” according to the report published on February 13th, 2019.

H.C. Wainwright gave a rating of “Buy” to GALT, setting the target price at $10 in the report published on December 07th of the previous year.

GALT Trading at 31.42% from the 50-Day Moving Average

After a stumble in the market that brought GALT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.11% of loss for the given period.

Volatility was left at 7.60%, however, over the last 30 days, the volatility rate increased by 15.16%, as shares surge +33.82% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +28.62% upper at present.

During the last 5 trading sessions, GALT rose by +36.33%, which changed the moving average for the period of 200-days by +26.61% in comparison to the 20-day moving average, which settled at $2.80. In addition, Galectin Therapeutics Inc. saw 27.27% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at GALT starting from Uihlein Richard E, who purchase 10,000 shares at the price of $2.55 back on Sep 04. After this action, Uihlein Richard E now owns 7,893,191 shares of Galectin Therapeutics Inc., valued at $25,500 using the latest closing price.

FREEMAN KEVIN D, the Director of Galectin Therapeutics Inc., purchase 5,000 shares at $2.57 during a trade that took place back on Sep 04, which means that FREEMAN KEVIN D is holding 25,000 shares at $12,848 based on the most recent closing price.

Stock Fundamentals for GALT

The total capital return value is set at -51.11, while invested capital returns managed to touch -50.60. Equity return is now at value -42.80, with -38.50 for asset returns.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Based on Galectin Therapeutics Inc. (GALT), the company’s capital structure generated 0.20 points at debt to equity in total, while total debt to capital is 0.20. Total debt to assets is 0.19, with long-term debt to equity ratio resting at 0.12. Finally, the long-term debt to capital ratio is 0.11.

The liquidity ratio also appears to be rather interesting for investors as it stands at 17.10.

Related Articles

Looking Closely at the Growth Curve for Coty Inc. (COTY)

Coty Inc. (NYSE:COTY) went down by -1.53% from its latest closing price compared to the recent 1-year high of $13.42. The company’s stock price...

Wall Street Pummels NEM After Recent Earnings Report

Newmont Corporation (NYSE:NEM) went down by -1.53% from its latest closing price compared to the recent 1-year high of $72.22. The company’s stock price...

Daily High to Daily Low: Is It Safe to Buy Globalstar Inc. (GSAT)?

Globalstar Inc. (AMEX:GSAT) went down by -1.52% from its latest closing price compared to the recent 1-year high of $0.60. The company’s stock price...

Latest Posts

Looking Closely at the Growth Curve for Coty Inc. (COTY)

Coty Inc. (NYSE:COTY) went down by -1.53% from its latest closing price compared to the recent 1-year high of $13.42. The company’s stock price...

Wall Street Pummels NEM After Recent Earnings Report

Newmont Corporation (NYSE:NEM) went down by -1.53% from its latest closing price compared to the recent 1-year high of $72.22. The company’s stock price...

Daily High to Daily Low: Is It Safe to Buy Globalstar Inc. (GSAT)?

Globalstar Inc. (AMEX:GSAT) went down by -1.52% from its latest closing price compared to the recent 1-year high of $0.60. The company’s stock price...

We Analyzed the Future Direction of SITE Centers Corp. (SITC), Here is What We Found

SITE Centers Corp. (NYSE:SITC) went down by -1.51% from its latest closing price compared to the recent 1-year high of $15.85. The company’s stock...

Can VEREIT Inc. (VER) Remain Competitive?

VEREIT Inc. (NYSE:VER) went down by -1.50% from its latest closing price compared to the recent 1-year high of $10.18. The company’s stock price...